Tactile Systems Technology Inc (TCMD) · Insider trading
What Tactile Systems Technology's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$2.02M
3 insiders, 7% under a plan
Net, 12 months
−$2.02M
bought less sold
Latest filing
2026-08-12
filings read to 2026-10-20
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Dodd Sheri LouiseDirector, Chief Executive Officer | – | $1.20M | 6 | 2026-08-10 | 232,907 |
| Burns KristieSr. VP Mktg & Clinical Affairs | – | $618,519 | 6 | 2026-02-24 | 82,581 |
| Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | – | $606,959 | 7 | 2026-05-11 | 130,188 |
| Reuvers Daniel L.Director | – | $560,981 | 2 | 2025-02-25 | 214,604 |
| Burke William WDirector | – | $31,911 | 1 | 2025-05-08 | 48,520 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Dodd Sheri LouiseDirector, Chief Executive Officer | Sale | 10,978 | 29.44 | $323,192 | 232,907 | Form 4 |
| 2026-05-11 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Sale | 4,631 | 24.49 | $113,413 | 130,188 | Form 4 |
| 2026-02-24 | Dodd Sheri LouiseDirector, Chief Executive Officer | Sale | 10,993 | 28.94 | $318,137 | 243,885 | Form 4 |
| 2026-02-24 | Burns KristieSr. VP Mktg & Clinical Affairs | Sale | 6,246 | 28.94 | $180,759 | 82,581 | Form 4 |
| 2026-02-24 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Sale | 7,701 | 28.94 | $222,867 | 134,819 | Form 4 |
| 2026-02-23 | Dodd Sheri LouiseDirector, Chief Executive Officer | Sale | 14,703 | 28.28 | $415,801 | 255,415 | Form 4 |
| 2026-02-23 | Dodd Sheri LouiseDirector, Chief Executive Officer | Sale | 537 | 28.69 | $15,407 | 254,878 | Form 4 |
| 2026-02-23 | Burns KristieSr. VP Mktg & Clinical Affairs | Sale | 4,279 | 28.28 | $121,010 | 88,987 | Form 4 |
| 2026-02-23 | Burns KristieSr. VP Mktg & Clinical Affairs | Sale | 160 | 28.69 | $4,590 | 88,827 | Form 4 |
| 2026-02-23 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Sale | 5,322 | 28.28 | $150,506 | 142,716 | Form 4 |
| 2026-02-23 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Sale | 196 | 28.69 | $5,623 | 142,520 | Form 4 |
| 2026-01-02 | Burns KristieSr. VP Mktg & Clinical Affairs | Saleplan | 5,139 | 28.85 | $148,260 | 72,401 | Form 4 |
| 2025-08-08 | Dodd Sheri LouiseDirector, Chief Executive Officer | Sale | 7,762 | 12.36 | $95,938 | 173,479 | Form 4 |
| 2025-05-12 | Birkemeyer Elaine M.Chief Financial Officer | Saleplan | 2,921 | 9.94 | $29,035 | 99,111 | Form 4 |
| 2025-05-08 | Dodd Sheri LouiseDirector, Chief Executive Officer | Sale | 3,149 | 9.83 | $30,955 | 181,241 | Form 4 |
| 2025-05-08 | Burke William WDirector | Saleplan | 3,300 | 9.67 | $31,911 | 48,520 | Form 4 |
| 2025-02-25 | Reuvers Daniel L.Director | Saleplan | 28,338 | 14.18 | $401,833 | 214,604 | Form 4 |
| 2025-02-25 | Burns KristieSr. VP Mktg & Clinical Affairs | Sale | 6,468 | 14.40 | $93,139 | 77,540 | Form 4 |
| 2025-02-25 | Birkemeyer Elaine M.Chief Financial Officer | Saleplan | 2,066 | 14.51 | $29,978 | 102,032 | Form 4 |
| 2025-02-24 | Birkemeyer Elaine M.Chief Financial Officer | Saleplan | 3,778 | 14.70 | $55,537 | 104,098 | Form 4 |
| 2025-02-24 | Burns KristieSr. VP Mktg & Clinical Affairs | Sale | 4,830 | 14.65 | $70,760 | 84,008 | Form 4 |
| 2025-02-24 | Reuvers Daniel L.Director | Saleplan | 10,938 | 14.55 | $159,148 | 242,942 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
37 × grant or award2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-05-06 | Burke William WDirector | Grant or award A | +6,521 | – | 55,041 | Form 4 |
| 2026-05-06 | Volkart Carmen BDirector | Grant or award A | +6,521 | – | 44,219 | Form 4 |
| 2026-05-06 | Pearson AndreaDirector | Grant or award A | +6,521 | – | 7,373 | Form 4 |
| 2026-05-06 | Huggenberger RaymondDirector | Grant or award A | +6,521 | – | 62,841 | Form 4 |
| 2026-05-06 | Shafer David BrentDirector | Grant or award A | +6,521 | – | 55,343 | Form 4 |
| 2026-05-06 | Asbury Valerie L.Director | Grant or award A | +6,521 | – | 55,343 | Form 4 |
| 2026-05-06 | Washington Boyd VindellDirector | Grant or award A | +6,521 | – | 41,768 | Form 4 |
| 2026-05-06 | King Laura G.Director | Grant or award A | +6,521 | – | 25,569 | Form 4 |
| 2026-03-09 | Pearson AndreaDirector | Grant or award A | +852 | – | 852 | Form 4 |
| 2026-02-20 | Dodd Sheri LouiseDirector, Chief Executive Officer | Grant or award A | +19,751 | – | 241,902 | Form 4 |
| 2026-02-20 | Dodd Sheri LouiseDirector, Chief Executive Officer | Grant or award A | +28,216 | – | 270,118 | Form 4 |
| 2026-02-20 | Burns KristieSr. VP Mktg & Clinical Affairs | Grant or award A | +3,490 | – | 82,085 | Form 4 |
| 2026-02-20 | Burns KristieSr. VP Mktg & Clinical Affairs | Grant or award A | +4,058 | – | 86,143 | Form 4 |
| 2026-02-20 | Burns KristieSr. VP Mktg & Clinical Affairs | Grant or award A | +7,123 | – | 93,266 | Form 4 |
| 2026-02-20 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Grant or award A | +3,579 | – | 125,698 | Form 4 |
| 2026-02-20 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Grant or award A | +6,765 | – | 132,463 | Form 4 |
| 2026-02-20 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Grant or award A | +15,575 | – | 148,038 | Form 4 |
| 2026-02-19 | Dodd Sheri LouiseDirector, Chief Executive Officer | Grant or award A | +48,672 | – | 222,151 | Form 4 |
| 2026-02-19 | Burns KristieSr. VP Mktg & Clinical Affairs | Grant or award A | +6,194 | – | 78,595 | Form 4 |
| 2026-02-19 | Birkemeyer Elaine M.CHIEF FINANCIAL OFFICER | Grant or award A | +23,008 | – | 122,119 | Form 4 |
| 2025-05-07 | Washington Boyd VindellDirector | Grant or award A | +16,078 | – | 35,247 | Form 4 |
| 2025-05-07 | Volkart Carmen BDirector | Grant or award A | +16,078 | – | 37,698 | Form 4 |
| 2025-05-07 | Shafer David BrentDirector | Grant or award A | +16,078 | – | 48,822 | Form 4 |
| 2025-05-07 | King Laura G.Director | Grant or award A | +16,078 | – | 19,048 | Form 4 |
| 2025-05-07 | Huggenberger RaymondDirector | Grant or award A | +16,078 | – | 56,320 | Form 4 |
| 2025-05-07 | Asbury Valerie L.Director | Grant or award A | +16,078 | – | 48,822 | Form 4 |
| 2025-05-07 | Burke William WDirector | Grant or award A | +16,078 | – | 51,820 | Form 4 |
| 2025-03-11 | Reuvers Daniel L.Director | Gift G | −68,162 | – | 146,442 | Form 4 |
| 2025-03-11 | Reuvers Daniel L.Director | Gift G | +68,162 | – | 68,162 | Form 4 |
| 2025-02-20 | Dodd Sheri LouiseDirector, Chief Executive Officer | Grant or award A | +20,108 | – | 118,721 | Form 4 |
| 2025-02-20 | Dodd Sheri LouiseDirector, Chief Executive Officer | Grant or award A | +65,669 | – | 184,390 | Form 4 |
| 2025-02-20 | King Laura G.Director | Grant or award A | +2,970 | – | 2,970 | Form 4 |
| 2025-02-20 | Birkemeyer Elaine M.Chief Financial Officer | Grant or award A | +3,446 | – | 64,741 | Form 4 |
| 2025-02-20 | Birkemeyer Elaine M.Chief Financial Officer | Grant or award A | +6,887 | – | 71,628 | Form 4 |
| 2025-02-20 | Birkemeyer Elaine M.Chief Financial Officer | Grant or award A | +36,248 | – | 107,876 | Form 4 |
| 2025-02-20 | Burns KristieSr. VP Mktg & Clinical Affairs | Grant or award A | +3,359 | – | 68,128 | Form 4 |
| 2025-02-20 | Burns KristieSr. VP Mktg & Clinical Affairs | Grant or award A | +4,131 | – | 72,259 | Form 4 |
| 2025-02-20 | Burns KristieSr. VP Mktg & Clinical Affairs | Grant or award A | +16,579 | – | 88,838 | Form 4 |
| 2025-02-20 | Reuvers Daniel L.Director | Grant or award A | +15,853 | – | 253,880 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.